Month: August 2020

Pacific Mercantile Bancorp Reports Second Quarter 2020 Operating Results

Written by Customer Service on August 5, 2020. Posted in Earnings Releases And Operating Results.

Second Quarter SummaryNet income of $1.9 million, or $0.08 per fully diluted shareFunded $280.3 million of Paycheck Protection Program (“PPP”) loans for almost 700 companies representing over 30,000 employeesExecution of PPP was the primary driver for the increase in interest income from loans over last quarter of $1.5 million, or 10.9%, and an increase in total interest income of $811 thousand, or 5.5%Ongoing focus on reducing costs of deposits in combination with the Federal Reserve’s rate cuts resulted in a decrease in interest expense over last quarter of $1.0 million, or 31.4%Implementation of cost savings initiatives contributed to a reduction in noninterest expense over last quarter by $786 thousand, or 8.1%Provision for loan and lease losses of $2.9 million primarily as a result of net charge-offs of $2.2 million, an increase...

Malvern Bancorp, Inc. Reports Third Fiscal Quarter 2020 Results

Written by Customer Service on August 5, 2020. Posted in Earnings Releases And Operating Results.

PAOLI, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) — Malvern Bancorp, Inc. (NASDAQ: MLVF) (the “Company”), the parent company of Malvern Bank, National Association (“Malvern” or the “Bank”), today reported operating results for the third fiscal quarter ended June 30, 2020. Net income for the quarter ended June 30, 2020 amounted to $1.5 million, or $0.19 per fully diluted common share, compared with net income of $2.7 million, or $0.35 per fully diluted common share, for the quarter ended June 30, 2019. The decreases in net income and diluted earnings per share from the third quarter of 2019 were primarily due to an increase in the provision for loan losses and a decrease in net interest income. The Company recorded a provision for loan losses of $435,000 for the quarter ended June 30, 2020, an increase of $379,000 compared to the quarter...

XDD Acquires Anexsys Group Limited in London to Expand International Presence in UK

Written by Customer Service on August 5, 2020. Posted in Mergers And Acquisitions.

MISSION, Kan., Aug. 05, 2020 (GLOBE NEWSWIRE) — Xact Data Discovery (XDD), a leading international provider of eDiscovery, data management and managed review services for law firms and corporations, announces the acquisition of Anexsys Group Limited, an eDiscovery services company based in London, UK. David Moran, XDD President and COO, states, “Complementing our recent domestic acquisitions, adding Anexsys to the XDD family enables XDD to expand eDiscovery, Forensics and Managed Review services in the UK. Based strategically in London, UK, the Anexsys team has earned a solid reputation for providing exemplary eDiscovery consultancy services to a wide variety of law firms, corporations and government agencies. Mirroring XDD’s customer-centric culture, we look forward to jointly servicing clients as we continue to expand our footprint...

NextCure to Present at BTIG Virtual Biotechnology Conference

Written by Customer Service on August 5, 2020. Posted in Public Companies.

BELTSVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the BTIG Virtual Biotechnology Conference on August 11th at 9:30 am Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™...

Innovative Credit Card Processor Clearent, LLC Switches to BIO-key’s PortalGuard Identity and Access Management Solution to Secure Customer Access and Deliver Secure Reset Capabilities

Written by Customer Service on August 5, 2020. Posted in Public Companies.

WALL, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced that Clearent, LLC selected BIO-key’s PortalGuard IAM solution to secure customer self-enrollment, account recovery and online access to its banking applications. Clearent is one of the fastest-growing credit card processing companies, processing $14 billion in annual transaction volume for 45,000 plus merchants nationwide. Clearent customers will also benefit from the security and convenience of PortalGuard’s Single Sign-on functionality utilized by customers for frictionless access to the Clearent’s payment portal.Clearent opted to use PortalGuard to replace its prior identity application. BIO-key’s PortalGuard IAM solution offered...

Salarius Announces Issuance of New Patent for Seclidemstat by European Patent Office

Written by Customer Service on August 5, 2020. Posted in Public Companies.

HOUSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced the continued enhancement of the intellectual property (IP) portfolio governing its lead investigational drug candidate, seclidemstat. The European Patent Office (EPO) recently announced that the European Patent EP2744330, exclusively licensed to Salarius from the University of Utah Research Foundation, was issued on July 15, 2020. The European patent covers composition of matter and methods of use for seclidemstat, a potent reversible inhibitor of the LSD1 enzyme which is currently the subject of a Phase 1/2 clinical trial for Ewing sarcoma, a rare pediatric bone cancer, and a Phase 1/2 trial in advanced solid tumors (AST). Salarius intends...

Pacira Announces Publication of Phase 4 Study of EXPAREL in Cesarean Section Procedures in Anesthesia & Analgesia

Written by Customer Service on August 5, 2020. Posted in Public Companies.

– Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery –PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) administered via transversus abdominis plane (TAP) field block in patients undergoing Cesarean section (C-section) have been published in Anesthesia and Analgesia. In this study, EXPAREL achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption through 72 hours. EXPAREL also achieved statistical significance for reduction in percentage of opioid-spared patients through 72 hours.This was a multicenter, randomized, double-blind study across 13...

BioDelivery Sciences Reports Strong Q2 2020 Results

Written by Customer Service on August 5, 2020. Posted in Public Companies.

Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 MillionSecond Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 MillionBELBUCA and Symproic® Each Reach All Time High TRx Volume and Market ShareConference Call and Webcast Scheduled for 8:30 AM EST TodayRALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter ended June 30, 2020, as well as the following operational and performance highlights.Key Business HighlightsTotal Company net revenue for the second quarter increased by 23% versus the prior year period to $36.6 million. This growth was driven...

Black Diamond Therapeutics to Present at Upcoming Investor Conferences

Written by Customer Service on August 5, 2020. Posted in Public Companies.

CAMBRIDGE, Mass. and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences:The 2020 Wedbush PacGrow Healthcare Conference. The presentation will take place on Wednesday, August 12, 2020, at 10:20 AM ET.The 40th Annual Canaccord Genuity Growth Conference. The presentation will take place on Thursday, August 13, 2020, at 3:30 PM ET.Live webcasts of each presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay...

ContextVision Extraordinary General Meeting

Written by Customer Service on August 5, 2020. Posted in Public Companies.

On the 5th of August 2020, ContextVision held an Extraordinary General Meeting in Stockholm.The Board’s proposal for adoption of new articles of association was approvedThe Board’s proposal for decision on the share split of the company’s share was approvedNo other matters were processed at the meeting.For further information, please contact:Ann-Charlotte Linderoth (CFO)tel +46 (0)8 7503550, e-mail ann-charlotte.linderoth@contextvision.se###About ContextVisionContextVision is a medical technology software company specialized in image analysis and artificial intelligence. As the global market leader within image enhancement, we are a trusted partner to leading manufacturers of ultrasound, X-ray and MRI equipment around the world.Our expertise is to develop powerful software products, based on proprietary technology and...

Month: August 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals